Posts Tagged ‘diabetes’

RSS

April 15th, 2015

Diabetes Drugs Get Neither Restrictions Nor Endorsements from FDA Committee

Two diabetes drugs survived a meeting of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee on Tuesday. Rejecting recommendations from critics that the drugs should either be withdrawn or get new restrictions on use, the committee voted against any harsh measures, recommending only that information from two neutral clinical  trials be added to the drugs’ labels. The two trials were […]


December 16th, 2014

No Advantage for Low-Glycemic-Index Diet

In recent years the glycemic index (GI), a measure of a carbohydrate’s impact on blood sugar, has assumed a major role in discussions about diets and nutrition. Now a study suggests that by itself, within the context of an otherwise healthy diet, GI may not be an important factor in improving cardiovascular risk. In a paper […]


December 8th, 2014

Selections from Richard Lehman’s Literature Review: December 8th

This week’s topics include the surgical treatment of moderate ischemic mitral regurgitation, the Mediterranean diet and telomere length, and more.


October 6th, 2014

Selections from Richard Lehman’s Literature Review: October 6th

This week’s topics include medical device safety and effectiveness, familial hypercholesterolemia, and more.


September 30th, 2014

Genetic Analysis Fails to Support Vitamin D to Prevent Diabetes

A vitamin D pill can’t substitute for a healthy diet and sunshine, a new genetic study published in The Lancet Diabetes & Endocrinology suggests. In recent years many people have been seduced by observational studies that found low levels of vitamin D in people who developed type 2 diabetes. The new study instead suggests that the association […]


September 29th, 2014

Selections from Richard Lehman’s Literature Review: September 29th

This week’s topics include prevalence and incidence trends in diabetes in the U.S., quality of life outcomes with CABG in ischemic left ventricular dysfunction, and more.


September 18th, 2014

FDA Approves New Once-Weekly GLP-1 Receptor Agonist for Type 2 Diabetes

The FDA said today that it had approved dulaglutide, Lilly’s once-weekly injection to control blood sugar in adults with type 2 diabetes. The drug will be marketed under the brand name of Trulicity. The FDA said that the safety and efficacy of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, had been studied in  3,342 type 2 diabetics. The drug […]


September 9th, 2014

Lower Rate of Microvascular Complications in Statin Users Who Develop Diabetes

In recent years, the medical community has become increasingly aware that taking statins can result in slightly higher glucose levels, and this can lead to a diagnosis of diabetes in a small but statistically significant number of people. But it has been unclear whether the diagnosis of diabetes in people taking statins also places them […]


August 12th, 2014

What Can We Really Deduce from ACCORD?

For Kasia Lipska, post hoc analyses of intensive glucose lowering in the ACCORD trial require greater scrutiny.


July 17th, 2014

Clinical Events vs. Quality of Life: An Insider’s View of TACT

TACT investigator Gervasio Lamas provides perspective on two new TACT papers that appear to have contradictory results.